Skip to main content

Table 3 Overall and Progression free survival in Patients receiving only PD-1 therapy

From: Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

Cohort A (No Metformin) Cohort B (Metformin)
Overall Survival
 • 64.6% patients alive at 1 year • 100% patients alive at 1 year
 • 55.4% patients alive at 2 years • 72.9% patients alive at 2 years
Progression Free Survival
 • 36.3% patients free from progression at 1 year • 59.6% patients free from progression at 1 year
 • 27.2% patients free from progression at 2 years • 47.6% patients free from progression at 2 years